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Abstract
Background: The aim of this study is to investigate if early treatment with levodopa has a beneficial disease
modifying effect on Parkinson’s disease (PD) symptoms and functional health, improves the ability to (maintain)
work, and reduces the use of (informal) care, caregiver burden, and costs. Additionally, cost-effectiveness and
cost-utility of early levodopa treatment will be assessed.
Methods: To differentiate between the direct symptomatic effects and possible disease modifying effects
of levodopa, we use a randomised delayed-start double-blind placebo-controlled multi-centre trial design.
Patients with early stage PD whose functional health does not yet necessitate initiation of PD-medication
will be randomised to either 40 weeks of treatment with levodopa/carbidopa 100/25 mg TID including 2 weeks
of dose escalation or to 40 weeks placebo TID. Subsequently, all patients receive levodopa/carbidopa 100/25 mg
TID for 40 weeks. There are 8 assessments: at baseline and at 4, 22, 40, 44, 56, 68, and 80 weeks. The primary
outcome measure is the difference in the mean total Unified Parkinson’s Disease Rating Scale scores between the
early- and delayed-start groups at 80 weeks. Secondary outcome measures are rate of progression, the AMC Linear
Disability Score, side effects, perceived quality of life with the Parkinson’s Disease Questionnaire-39, the European
Quality of Life-5 Dimensions (EQ-5D), ability to (maintain) work, the use of (informal) care, caregiver burden, and
costs. 446 newly diagnosed PD patients without impaired functional health need to be recruited in order to detect
a minimal clinical relevant difference of 4 points on the total UPDRS at 80 weeks.
Discussion: The LEAP-study will provide insights into the possible disease modifying effects of early levodopa.
Trial registration: ISRCTN30518857, EudraCT number 2011-000678-72
Keywords: Parkinson’s disease, Levodopa, Randomised delayed-start placebo-controlled trial, Disease modifying
Background
Parkinson’s disease (PD) is a neurodegenerative disease
characterised by the progression of bradykinesia, tremor,
and rigidity, as well as a wide range of non-motor symp-
toms. The core motor symptoms are caused by the
degeneration of dopamine producing neurons [1, 2]. The
mainstay of the treatment consists of dopamine
replacement either with the dopamine precursor levodopa
or with directly acting dopamine receptor agonists (DA).
Although levodopa is inexpensive and very efficacious
[3, 4], many neurologists tend to delay initiation and
timely adjustments of levodopa. One concern is that
levodopa could be toxic, although this has never been
supported by the results of clinical studies [5]. Another
reason is the concern for side effects such as dyskinesias
[1, 6]. Although levodopa-sparing strategies indeed delay
the onset of dyskinesias compared to levodopa mono-
therapy, sooner or later all patients need levodopa [2].
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The results of the ELLDOPA study suggest that levo-
dopa may have a beneficial disease modifying effect in
addition to the well-known direct symptomatic effect
[3]. To date, other studies concerning disease modifying
effects of dopaminergic drugs have been inconclusive or
negative [7]. More knowledge of possible disease modify-
ing effects of levodopa may improve the use of levodopa
in daily clinical practice.
Therefore, we aim to investigate whether the early
start of levodopa has a beneficial disease modifying ef-
fect on PD symptoms and functional health, subse-
quently improves patient’s quality of life and the ability
to (maintain) work, and reduces the use of (informal)
care, caregiver burden and costs. We will also assess
cost-effectiveness and cost-utility of early levodopa
treatment.
Methods
Trial design
To differentiate between the direct symptomatic effects
and possible disease modifying effects of levodopa, we
use a randomised delayed-start double-blind placebo-
controlled design (Figs. 1 and 2). Seven academic hospi-
tals and 43 community hospitals in the Netherlands are
recruiting patients. Study nurses are trained to perform
all study procedures.
Study participants
The inclusion criteria are (a) idiopathic PD with
bradykinesia and at least two of the following signs:
resting tremor, rigidity or asymmetry; (b) newly diag-
nosed PD within the past two years; (c) age 30 years
and older; (d) a life expectancy of more than two
years; and (e) no limitations in functional health for
which the patient needs PD-medication. Exclusion cri-
teria are (a) tremor as most prominent symptom, such
as a severe resting tremor that is present almost con-
tinuously or a tremor of medium to large amplitude
which results in functional disability, such as interfer-
ing with feeding; (b) previous treatment with PD-
medication; (c) cognitive impairments, defined as a
Mini Mental State Examination (MMSE) of 23 points
or lower; (d) a score of more than 28 points on the
Beck Depression Inventory II (BDI-II); (e) diagnosis of
depression by a psychiatrist in the last year; (f ) history
of psychosis; (g) the presence of signs indicating atyp-
ical or secondary parkinsonism; (h) untreated closed-
angle glaucoma; (i) alcohol abuse; (j) possible preg-
nancy; (k) legally incompetent adults, and (l) inability
to provide written informed consent.
Study procedures and randomisation
If a patient is eligible, the neurologist briefly introduces
the study and asks the patient permission to send con-
tact information to the coordinating research nurse at
the central study hospital (Academic Medical Center,
University of Amsterdam). The neurologist provides the
patient with written information about the study and in-
forms the research nurse at the central study hospital.
Subsequently, the research nurse in the central study
hospital registers the patient in the Local Logistics Data-
base. There are five research nurses in five study
hospitals based throughout the Netherlands (Academic
Medical Center, Atrium-Orbis Medical Center Heerlen/
Sittard, Leiden University Medical Center, University
Medical Center Groningen, and Radboud University
Medical Center). After the patient has been registered,
the research nurse based closest to the hospital from
where the patient has been put forward is informed.
Within three days, the research nurse contacts the pa-
tient by phone to answer questions about the study and
the nurse makes an appointment to further explain the
Fig. 1 Delayed-start design. Studies with a delayed-start design investigate two agents: active treatment (solid line) and controlled treatment
(dashed line). In phase 1, patients are randomised to either active (levodopa) or controlled (placebo) treatment. In phase 2, both groups receive
active treatment
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study if necessary. Patients are required to give a written
informed consent to participate.
There are eight assessments, which take place at base-
line, four weeks, 22 weeks, 40 weeks, 44 weeks, 56 weeks,
68 weeks, and 80 weeks – respectively Visits 1 to 8. At
the end of Visit 1, patients are randomised to 40 weeks
treatment with levodopa/carbidopa (early-start group) or
to 40 weeks placebo (delayed-start group). The first
40 weeks of the study is called phase 1. Subsequently, all
patients receive 40 weeks levodopa/carbidopa – phase 2
(Fig. 1).
Patients in the early-start group take levodopa/carbidopa
capsules according to a starting-schedule during weeks 1
and 2, followed by levodopa/carbidopa 100/25 mg tablets
TID during weeks 3 to 40 (Table 1). In weeks 41 and 42,
they take levodopa/carbidopa 100/25 mg capsules TID. Pa-
tients in the delayed-start group take placebo capsules TID
during the first 2 weeks, followed by placebo tablets TID
during weeks 3 to 40. In weeks 41 and 42, they take
levodopa/carbidopa capsules according to a starting-
schedule (Table 1). From weeks 43 to 80, all patients
receive the levodopa/carbidopa 100/25 mg tablets
through their regular pharmacies. In the first 42 weeks
of the study, the placebo capsules and tablets are iden-
tical in appearance, smell, and taste compared to the
levodopa/carbidopa capsules and tablets; they are
produced by ACE Pharmaceuticals (Zeewolde, The
Netherlands) according to Good Manufacturing Prac-
tice guidelines.
If the treating neurologist finds that the patient needs
additional treatment during the placebo-controlled
phase, the patient immediately starts with the capsules
initially designated for weeks 41 and 42 and subse-
quently will use levodopa/carbidopa 100/25 mg TID.
This means that - irrespective of initial treatment alloca-
tion – the patient is certain to take levodopa/carbidopa
from that moment on. Patients that subsequently require
additional treatment will receive levodopa/carbidopa
Fig. 2 Delayed-start design with beneficial effect of early treatment with levodopa. If a beneficial disease modifying effect of levodopa exists,
patients in the early-start group will perform better at the end of the study than patients in the delayed-start group if phase 1 is sufficiently long
and if the beneficial disease modifying effect is maintained during phase 2. The small improvement of the delayed-start group at the start of
phase 1 and of the early-start group at the start of phase 2 represents the placebo-effect
Table 1 Treatment schedule weeks 1 to 80
Early group Delayed group
Morning Noon Evening Morning Noon Evening
Phase 1 Week 1 (capsules) 50/12.5 Placebo 50/12.5 Placebo Placebo Placebo
Week 2 (capsules) 100/25 50/12.5 50/12.5 Placebo Placebo Placebo
Weeks 3 to 40 (tablets) 100/25 100/25 100/25 Placebo Placebo Placebo
Phase 2 Week 41 (capsules) 100/25 100/25 100/25 50/12.5 Placebo 50/12.5
Week 42 (capsules) 100/25 100/25 100/25 100/25 50/12.5 50/12.5
Week 43 to 80 (tablets) 100/25 100/25 100/25 100/25 100/25 100/25
Doses are written as levodopa/carbidopa milligram
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200/50 mg TID. If a patient needs more treatment, the
choice and dose of additional medication is left to the
discretion of the treating neurologist. If a patient does
not follow the study protocol, this is registered; we aim
to perform all further procedures and measurements ac-
cording to the study protocol.
Randomisation is performed by a central website based
computer program in 1:1 ratio (Fig. 1) and stratified by
type of hospital (university medical centre versus non-
university medical centre), age (below 65 years or
65 years and older), and symptom duration (shorter than
0.5 year or 0.5 year and longer), using variable permuted
blocks. Study personnel, research nurses, neurologists,
and patients are blinded to the treatment allocation at
all times. ACE Apothecary (ACE Apotheek, Zeewolde,
The Netherlands) allocates the randomised patient to a
medication number that corresponds with the treatment
group and ACE Apothecary is responsible for packaging,
labelling and shipment of the study medication during
the first 42 weeks of the study. Randomisation data are
kept strictly confidential and are accessible only to
authorised persons at ACE Pharmaceuticals and ACE
Apothecary until the database is unlocked at the end of
the study. All data will be entered in a central website
based database before the database is unlocked.
Approval of the medical ethical committee of the Aca-
demic Medical Center was obtained. The LEAP-study is
conducted according to the principles of the Declaration
of Helsinki (version 2008). Study monitoring and data
management are performed in accordance with the
International Conference on Harmonisation - Good
Clinical Practice guidelines. This is an investigator-
initiated study. None of the funding organisations has
influence on the design or execution of the trial, the ana-
lysis of the study data, or the publication of articles con-
cerning the study data.
Outcome measures
The primary clinical outcome measure is the difference
in the mean total Unified Parkinson’s Disease Rating
Scale (UPDRS) scores between the early- and delayed-
start groups at 80 weeks (Table 2) [8]. Secondary end-
points are (a) progression of symptoms between Visit 2
and Visit 4 (phase 1) and between Visit 5 and Visit 8
(phase 2) measured with the UPDRS; (b) disability mea-
sured with the AMC Linear Disability Score (ALDS), de-
fined as the between-group difference at 80 weeks
(Table 2) [9]; (c) between-group difference in mean total
UPDRS scores at 80 weeks and the progression of
UPDRS scores during phases 1 and 2 in patients who
followed the study ‘per protocol’; (d) between-group dif-
ference in mean total UPDRS scores at 80 weeks and the
progression of UPDRS scores during phases 1 and 2 in
patients with UPDRS scores in the highest quartile of
scores at baseline who followed the study ‘per protocol’;
(e) number of patients that need additional medication
during phases 1 and 2; (f ) cognitive impairment, mea-
sured with the MMSE (Table 2) [10]; (g) depression,
measured with the BDI-II (Table 2) [11]; (h) perceived
quality of life measured with the Parkinson’s Disease
Questionnaire-39 (PDQ-39) (Table 2) [12]; (i) quality ad-
justed life years (QALY), after applying existing scoring
algorithms to derive health utilities from observed Euro-
pean Quality of Life-5 Dimensions (EQ-5D) data
(Table 2) [13]; (j) working status and absence from paid
work measured with a standardised questionnaire; (k)
caregiver burden with a standardised questionnaire; (l)
resource utilisation outside of the participating hospitals
measured with a standardised questionnaire (for (j), (k)
and (l) we used an adjusted version of the Short Form -
Health and Labour Questionnaire [14, 15] and iMTA
Valuation of Informal Care Questionnaire targeted at the
study population [16]); (m) costs per unit decrease of
the UPDRS and costs per QALY [17, 18]; (n) number of
patients withdrawn from the study or lost to follow up;
(o) dyskinesias, measured with items 32 to 35 of the
UPDRS part IV; (p) levodopa-induced motor response
fluctuations throughout the course of the study mea-
sured with items 36 to 39 of the UPDRS part IV and
three standardised questions concerning wearing-off
phenomena (q) (serious) adverse events defined as the
frequency, severity, nature, and duration of any adverse
event throughout the course of the study.
Statistics
Based on the ELLDOPA study, we assume a mean base-
line UPDRS score of 28 points with a standard deviation
of 13 points and anticipate a mean UPDRS score in the
early-start group of 31 points (worsening of 3 points
during follow-up) and a mean UPDRS score in the
delayed-start group of 35 points (worsening of 7 points)
at the final outcome assessment at 80 weeks [3]. Assum-
ing that the common standard deviation is 13, a sample
size of 167 in each group will have 80 % power to detect
a difference in mean follow-up scores of 4 points, using
Table 2 Clinical rating scales
Clinical rating scale Domain Best score Worst score
UPDRS Parkinsonism 0 199
MMSE Cognition 30 0
BDI-II Depression 0 63
ALDS Disability 100 0
EQ-5D Quality of life - -
PDQ-39 Quality of life 0 100
UPDRS Unified Parkinson’s Disease Rating Scale, MMSE Mini Mental State
Examination, BDI-II Beck Depression Inventory II, ALDS AMC Linear Disability
Scale, EQ-5D European Quality of Life-5 Dimensions, PDQ-39 Parkinson’s
Disease Questionnaire-39
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a two-group t-test with a 0.05 two-sided significance
level. In the ELLDOPA study, a dropout rate of 22.2 %
was reported in the placebo group [3]. After 80 weeks,
the ADAGIO-study reported a total dropout rate of
24.4 % in the 1 mg delayed-start group and 19.2 % in the
2 mg delayed-start group. Based on these results, a total
withdrawal rate of 25 % was considered realistic [19]:
therefore, we plan to include 223 patients per treatment
arm, which means 446 patients in total (Fig. 3).
Data will be analyzed according to the intention-to-
treat principle. The main analysis of this trial consists of
a comparison between the trial treatment groups of the
primary outcome after 80 weeks. First, the follow-up dif-
ference of mean UPDRS scores between the treatment
arms will be crudely analyzed using a two-group t-test.
Second, the UPDRS follow-up scores will be further
investigated using analysis of covariance (ANCOVA),
taking into account patients’ UPDRS baseline values. To
account for the repeated measures within patients, a
random effects model will be used.
With regard to the comparisons of the secondary out-
come progression of symptoms during phases 1 and 2
we planned two separate analyses using a random effects
model to account for the repeated measures within pa-
tients (Fig. 2). For phase 1, we will use the measure-
ments of Visit 2 (4 weeks), Visit 3 (22 weeks) and Visit 4
(40 weeks) to estimate the difference in slopes between
the two treatment groups. A more progressive course
(steeper upward slope) in the placebo group during
phase 1 can reflect disease-modifying effects of levodopa.
This will be further explored by examining the slopes of
phase 2. Equal steepness of the slope during phase 2 in-
dicates that the (assumed) effect found in phase 1 is a
true disease-modifying effect. Therefore, we will use
measurements of Visit 5 (44 weeks), Visit 6 (56 weeks),
Visit 7 (68 weeks), and Visit 8 (80 weeks) to test equality
of progression in phase 2 with a non-inferiority test on
the difference between the slopes of the two treatment
arms using a non-inferiority margin of 0.055 UPDRS
points difference in increase per week (Fig. 2). The
slopes of the phases 1 and 2 will be analysed by both an
intention-to-treat and a per-protocol approach (see
below for further explanation).
As pointed out earlier, the main outcome in this study
will be the comparison between treatment arms on
UPDRS scores after the total study period of 80 weeks,
since this outcome relates to clinical practice. A differ-
ence of four points on the total UPDRS is considered to
be clinically relevant [20]. The comparisons of slopes in
the secondary analyses serve only to differentiate be-
tween the different types of treatment effects (direct
symptomatic vs disease modifying). Here we pre-specify
the possible inference made on these secondary analyses:
1) if a faster progression is found in the placebo group
during phase 1 and the non-inferiority assumption
assuming equal progression is met in phase 2, this
will be indicative of a true disease-modifying effect;
2) if a faster progression is found in the placebo group
during phase 1, but non-inferiority of slopes during
phase 2 is not demonstrated, then the results are
indicative of only direct symptomatic effects.
With regard to the comparisons of the other second-
ary outcomes (disability, number of patients that need
additional medication for PD, cognitive impairment,
mood, quality of life, ability to (maintain) work, use of
(informal) care, caregiver burden, levodopa-induced re-
sponse fluctuations, and side effects), we will use the
appropriate parametric and nonparametric statistics.
Cost-effectiveness and cost-utility analyses will be per-
formed from a societal perspective with the costs per
unit decrease on the UPDRS respectively, the costs per
QALY as outcomes. In all analyses statistical uncertain-
ties will be expressed in 95 % confidence intervals.
Subgroup analyses by type of hospital (university med-
ical centre versus non-university medical centre), age
Fig. 3 Flow chart LEAP-study. Taking into account a withdrawal
rate of 25 %, 446 patients need be enrolled to be able to show a
minimal clinically relevant difference of four points on the total
UPDRS at the end of the study
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and disease duration will be performed. Finally, two
additional ‘per protocol’ analyses will be carried, focusing
on (a) between-group difference in UPDRS scores at
80 week and the progression of UPDRS scores during
phases 1 and 2, and (b) between-group difference in
UPDRS scores at 80 weeks and the progression of
UPDRS scores during phases 1 and 2 in patients in the
highest quartile of scores at baseline. Patients will be ex-
cluded from the per protocol analysis if they needed
additional PD-medication during the study, if they did
not use the correct dose and type of medication (e.g., ex-
tended release levodopa formulations), or if they missed
either Visits 1, 2, 4, 5 or 8.
Discussion
To differentiate between the direct symptomatic effects
and possible disease modifying effects of levodopa, we
use a randomised delayed-start double-blind placebo-
controlled multi-centre trial design [21]. Some of the
choices in the study design warrant discussion.
First, we discuss the stratification for type of hospital,
age and disease duration. We stratified by type of hos-
pital (university medical centre versus non-university
medical centre) because of possible differing patient
characteristics. Stratification by age was chosen because
of the different rates of disease progression [22] and be-
cause younger patients have a higher risk to develop dys-
kinesias [23]. Furthermore, younger patients are working
more often than older patients, which may bias the cost-
effectiveness and cost-utility analyses. Stratification by
disease duration was chosen because it is more likely
that patients with longer disease duration at the time of
inclusion will need the addition of symptomatic medica-
tion earlier in the course of the study.
The second relevant issue is the approach we chose
for patients that need additional treatment during the
placebo-controlled phase of the study. If the treating
neurologist decides that a patient needs more treatment,
the patient will first start with the capsules initially des-
ignated for weeks 41 and 42, after which the patient is
certain to be taking levodopa/carbidopa – thereby indu-
cing a placebo effect in patients from the early-start
group (which are already on levodopa) and an additional
direct symptomatic effect of levodopa in patients from
the delayed-start group (which were on placebo) [19].
This procedure prevents unblinding.
Third, the placebo-controlled phase of 40 weeks was
chosen based on the results of the ELLDOPA study,
which suggested a possible disease modifying beneficial
effect of levodopa evident after 40 weeks of treatment
[3]. Ideally, the placebo-controlled phase of 40 weeks
would even be longer because if a disease modifying ef-
fect of levodopa exists, there would then be more time
for the slopes of the two treatment groups to diverge
further (Fig. 2). However, because of symptom progres-
sion, a placebo-controlled phase of more than 40 weeks
would result in the retention of progressively fewer pa-
tients in the placebo-controlled phase of the study, mak-
ing the placebo-controlled phase only slightly longer
because of the increasing lower numbers in the delayed-
start group – thereby diminishing the theoretical advan-
tage of a longer placebo-controlled phase. More import-
antly, poorer retention in the delayed-start group would
compromise the ability to show a difference between the
two groups and would potentially select out patients
with a milder or more slowly progressive disease course,
thereby diminishing a possible existing difference be-
tween the two groups. Also, a longer placebo-controlled
phase would result in higher costs in this investigator-
initiated study. A study design with an additional de-
layed-stop (at 40 weeks) arm was rejected because this
would require patients that typically need antiparkinson
medication at this point would experience increased
disability and discomfort due to having treatment
withheld.
Fourth, we chose a daily levodopa/carbidopa dose of
300/75 mg. In the ELLDOPA study, three levodopa/car-
bidopa doses (150/37.5 mg, 300/75 mg or 600/150 mg
daily) were tested and compared with placebo for
40 weeks, followed by a two-week washout period. The
results suggested a beneficial disease modifying effect of
levodopa in all treatment groups, thereby making a
strong case to choose the 150/37.5 mg daily dose for the
current study. However, in the 150/37.5 mg group, there
was also a higher dropout rate [3]. We considered a daily
treatment of levodopa/carbidopa 600/150 mg too high
because of the risk of more side effects [24] and because
in daily practice, starting-doses of levodopa are usually
lower.
All possible outcomes of the LEAP-study are likely to
have clinical implications. If the LEAP-study demon-
strates a beneficial disease modifying effect of the early
initiation of levodopa (Fig. 2), an argument can be made
for starting treatment as soon as the diagnosis of PD is
made. Subsequently, functional health and quality of life
may improve substantially – thereby prolonging the
period of higher social functioning and participation in
the workforce. If the study indicates that there is no dis-
ease modifying effect of levodopa, it can still be argued
that there is also no reason to delay the use of levodopa
early in the disease: after all, levodopa has a large symp-
tomatic effect. Important to note here is that motor
complications seem to relate more to disease severity
and disease duration than treatment duration [25]. The
third possible outcome is that the LEAP-study shows a
negative disease modifying effect after 40 weeks of
follow-up. Of course, this would be a strong argument
in favour of levodopa sparing strategies.
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The reason to perform two subgroup analyses – the
per protocol analysis and the per protocol analysis for
the patients with the highest quartile UPDRS-scores at
baseline – is to address the possibility that a direct
symptomatic effect of levodopa would mask a disease
modifying effect in this cohort with relatively mild
Parkinson’s disease.
Regardless of these possible outcomes of the LEAP-
study, no clear statement can yet be made about the ef-
fects of early or delayed starting with levodopa beyond
the study period. Some long-term effects of levodopa –
such as the development of dyskinesias and response
fluctuations – may take years to develop, which may off-
set any initial beneficial effect evident in the early start
group, speaking in terms of total quality-adjusted life
years and costs. In this light, the results of the open label
PD MED study have to be weighed carefully [2]. This
study did not show a difference between the PDQ-39
mobility scores of patients who started treatment with
levodopa as compared to patients starting with levodopa-
sparing therapy (DA or a Monoamine Oxidase-B inhibi-
tor). A high percentage of patients in the levodopa-
sparing arm also received levodopa in different dosages at
different times during the follow-up – thereby possibly
masking a disease modifying effect of levodopa. Interest-
ingly, the group that started with levodopa used a lower
levodopa equivalent dose at the end of the study. This
could be due to a beneficial disease modifying effect of
early levodopa, but could also be an artifact of the formula
used to calculate the levodopa equivalent dose.
Protocol
The full study-protocol can be accessed through the
study website www.leapamc.nl.
Abbrevations
ALDS: AMC Linear Disability Score; BDI-II: Beck Depression Inventory II;
DA: Dopamine receptor agonist; MMSE: Mini Mental State Examination;
PD: Parkinson’s disease; PDQ-39: Parkinson’s Disease Questionnaire-39;
UPDRS: Unified Parkinon’s Disease Rating Scale.
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